Explore

Trendline Trendline
Forlong Biotechnology to Present Clinical Data on FL115 at ASCO 2026

Forlong Biotechnology to Present Clinical Data on FL115 at ASCO 2026

Forlong Biotechnology to Present Clinical Data on FL115 at ASCO 2026
Trendline Trendline
Incyte Presents Phase 3 Tafasitamab Data at ASCO 2026, Supporting Global Regulatory Submissions

Incyte Presents Phase 3 Tafasitamab Data at ASCO 2026, Supporting Global Regulatory Submissions

Incyte Presents Phase 3 Tafasitamab Data at ASCO 2026, Supporting Global Regulatory Submissions
Trendline Trendline
Incyte Presents Phase 3 Tafasitamab Data at ASCO 2026, Supporting Global Submissions

Incyte Presents Phase 3 Tafasitamab Data at ASCO 2026, Supporting Global Submissions

Incyte Presents Phase 3 Tafasitamab Data at ASCO 2026, Supporting Global Submissions
Trendline Trendline
FDA Grants Fast Track Designation to Debiopharm's Ovarian Cancer Therapy

FDA Grants Fast Track Designation to Debiopharm's Ovarian Cancer Therapy

FDA Grants Fast Track Designation to Debiopharm's Ovarian Cancer Therapy
Trendline Trendline
Dizal to Present Key Developments in NSCLC Treatments at ASCO 2026

Dizal to Present Key Developments in NSCLC Treatments at ASCO 2026

Dizal to Present Key Developments in NSCLC Treatments at ASCO 2026
Trendline Trendline
IDEAYA Biosciences to Present Phase 2/3 Trial Data on Darovasertib at ASCO 2026

IDEAYA Biosciences to Present Phase 2/3 Trial Data on Darovasertib at ASCO 2026

IDEAYA Biosciences to Present Phase 2/3 Trial Data on Darovasertib at ASCO 2026
Trendline Trendline
Debiopharm's Ovarian Cancer Treatment Receives FDA Fast Track Designation

Debiopharm's Ovarian Cancer Treatment Receives FDA Fast Track Designation

Debiopharm's Ovarian Cancer Treatment Receives FDA Fast Track Designation
Trendline Trendline
NEOK Bio Highlights Bispecific Antibody Drug Conjugate Pipeline at AACR 2026

NEOK Bio Highlights Bispecific Antibody Drug Conjugate Pipeline at AACR 2026

NEOK Bio Highlights Bispecific Antibody Drug Conjugate Pipeline at AACR 2026
Trendline Trendline
Onchilles Pharma Unveils Promising Preclinical Data for NEU-002 Program at AACR 2026

Onchilles Pharma Unveils Promising Preclinical Data for NEU-002 Program at AACR 2026

Onchilles Pharma Unveils Promising Preclinical Data for NEU-002 Program at AACR 2026
Trendline Trendline
FDA Grants Priority Review for KEYTRUDA and Padcev Combination for Muscle-Invasive Bladder Cancer

FDA Grants Priority Review for KEYTRUDA and Padcev Combination for Muscle-Invasive Bladder Cancer

FDA Grants Priority Review for KEYTRUDA and Padcev Combination for Muscle-Invasive Bladder Cancer
Trendline Trendline
Immunitas Therapeutics Presents Promising Data on IMT-009 at AACR 2026

Immunitas Therapeutics Presents Promising Data on IMT-009 at AACR 2026

Immunitas Therapeutics Presents Promising Data on IMT-009 at AACR 2026
Trendline Trendline
Palleon Pharmaceuticals Initiates Clinical Trial for Innovative Cancer Therapy Targeting Immune Evasion

Palleon Pharmaceuticals Initiates Clinical Trial for Innovative Cancer Therapy Targeting Immune Evasion

Palleon Pharmaceuticals Initiates Clinical Trial for Innovative Cancer Therapy Targeting Immune Evasion